News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Email Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go Advanced Search Keywords Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard May 5, 2005 Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET) Apr 26, 2005 Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance Apr 20, 2005 Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R) Apr 18, 2005 Patent Infringement Suit Against Insmed Dismissed Apr 13, 2005 FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome Mar 16, 2005 Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004 Mar 15, 2005 Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16 Mar 15, 2005 Insmed Announces Completion of $35 Million Financing Mar 10, 2005 FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome Feb 22, 2005 Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims Show 5102550100 per page«1…56575859606162…69» Stay In The Loop Want to stay up to date on our news, events, and filings? Set up your email alerts. Sign Up View the latest Insmed Investor Presentation Download